The latest report from Astute Analytica, focusing on the worldwide Idiopathic Pulmonary Fibrosis Market, provides a thorough analysis of the factors poised to shape the market’s future direction. The report covers a range of sections, including Market Overview, Trends, Key Players, Segmentation, and more. Moreover, it offers valuable insights into past innovations and the current progress to present a comprehensive perspective on emerging trends.
Market Overview of Idiopathic Pulmonary Fibrosis Market
The Global Idiopathic Pulmonary Fibrosis Market generated US$ 2,073.9 million in 2021 and is estimated to reach US$ 4,298.8 million by 2030, growing at a compound annual growth rate (CAGR) of 9.4%.
Challenges
The prevalence of IPF lies in the lack of a standardized definition for diagnosis, leading to estimates in the general population ranging from 2-29 persons per 100,000. Furthermore, many cases of IPF remain untreated or are misdiagnosed, making it difficult to determine the true prevalence.
Approximately 5-10% of cases are linked to a family history of the disease. IPF typically affects individuals in their fifties and sixties, with a higher incidence in males than females. The anticipated growth of the IPF market reflects the industry’s recovery from the impact of COVID-19 and future growth trends.
Common symptoms of IPF include breathlessness, which can severely hinder daily activities, and a chronic cough lasting more than 8 weeks, affecting about 85% of IPF patients. Diagnosing IPF can be challenging due to similar symptoms with other lung disorders, necessitating various diagnostic procedures like pulmonary function tests, chest x-rays, and blood tests.
The report also provides insights into the market’s geographical scope, with the U.S. identified as the largest market, reaching $1,171.8 million in 2020 with the highest CAGR of 9.9%. In the United States, about 100,000 people are affected by IPF, with 30,000 to 40,000 new cases diagnosed annually.
Smoking is a primary risk factor for IPF, with over 16 million Americans affected by smoking-related diseases. The global IPF market includes therapies such as Esbriet (Pirfenidone) and OFEV, with Esbriet dominating the market in 2020. Both medications help individuals with IPF live longer, with MAPK Inhibitors (Esbriet) having the largest market share.
The market’s growth is driven by factors such as the aging population and the increasing number of smokers, both of which contribute to the rising prevalence of IPF. While IPF is more commonly diagnosed and progresses in older adults, its prevalence is low in the 18 to 60-year-old age group. The strong association between smoking and IPF also contributes to the disease’s prevalence and its impact on the Idiopathic pulmonary fibrosis market.
Competition Landscape of Idiopathic Pulmonary Fibrosis Market
Genentech, Inc.
Boehringer Ingelheim Pharma GmbH, and Co. Kg
MediciNova
FibroGen, Inc.
Kadmon Corporation, LLC
Promedior
Genkyotex
CelgeneCorporation
ProMetic LifeSciences
Biogen, Inc.
Merck and Co.
Novartis
Segmentation Overview of Idiopathic Pulmonary Fibrosis Market
By Therapy
Esbriet (Pirfenidone)
Ofev (Nintedanib)
Tipelukast
Pamrevlumab
KD025
PRM 151
GKT831
Others
By Country
The U.S.
The UK
France
Germany
Spain
Italy
Japan
Conclusion:
The Idiopathic Pulmonary Fibrosis (IPF) market is experiencing a surge in demand driven by several prominent trends. Improved awareness of IPF and its symptoms is prompting more individuals to seek early diagnosis and treatment, leading to a greater demand for related healthcare services and medications. Advances in diagnostic tools and techniques are facilitating more accurate identification of IPF cases, increasing the need for diagnostic services and early interventions.
Ongoing research and development efforts are introducing innovative therapies with enhanced outcomes for IPF patients, contributing to a growing demand for these treatments. Additionally, the global aging population, which is at higher risk for IPF, is naturally fueling demand for IPF-related healthcare services and treatments. Efforts to reduce smoking rates and promote lung health also play a role in driving demand for IPF prevention and treatment. Finally, the variations in IPF prevalence rates across different regions globally influence demand patterns, shaping the market’s trajectory.
Content Source: Idiopathic Pulmonary Fibrosis Market
YOU CAN CHECK OUR TRENDING BLOGS & REPORTS:
コメント